Who is it for?

Digistain® works biologically downstream using a proprietary method to measure markers at the protein level to deliver a robust and personalised risk score for cancer therapy guidance

Designed for invasive breast cancer patients who are:

Stage 1 - 2
up to 3 positive lymph nodes

Digistain is suitable for women with Stage 1 to Stage 2 invasive breast cancer that is hormone receptor-positive, HER2- and with no more than three affected lymph nodes.